925 resultados para poly-L-arginine
Resumo:
Alterations in the synthesis or enhanced inactivation of nitric oxide (NO) and increase in fibrin deposition in the vascular bed lead to an imbalance that can induced intravascular coagulation. NO is produced through L-arginine pathway by constitutive and inducible nitric oxide synthase (NOS). The inducible isoform can be activated by cytokines such as tumor necrosis factor alfa. We evaluated NO-induced tissue-plasminogen activator (t-PA) release from isolated aortic segments of Wistar rats measuring the fibrinolytic activity in the fibrin plate. Inhibition of NO biossynthesis with Nω-nitro-L-arginine (NωNLA) significantly attenuated the fibrinolytic activity (FA) evoked by aortic segments of this group (GII) compared to the saline group (GI). The administration of L-arginine produced restoration of FA in this group (GIII) treated with NωNLA suggesting that t-PA arising from segments of rat aorta is influenced by NO.
Resumo:
Microinjection of S-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) in the nucleus of the solitary tract (NTS) of conscious rats causes hypertension, bradycardia, and vasoconstriction in the renal, mesenteric, and hindquarter vascular beds. In the hindquarter, the initial vasoconstriction is followed by vasodilation with AMPA doses >5 pmol/100 nl. To test the hypothesis that this vasodilation is caused by activation of a nitroxidergic pathway in the NTS, we examined the effect of pretreatment with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 10 nmol/100 nl, microinjected into the NTS) on changes in mean arterial pressure, heart rate, and regional vascular conductance (VC) induced by microinjection of AMPA (10 pmol/100 nl in the NTS) in conscious rats. AMPA increased hindquarter VC by 18 ± 4%, but after pretreatment with L-NAME, AMPA reduced hindquarter VC by 16 ± 7% and 17 ± 9% (5 and 15 min after pretreatment, P < 0.05 compared with before pretreatment). Pretreatment with L-NAME reduced AMPA-induced bradycardia from 122 ± 40 to 92 ± 32 beats/min but did not alter the hypertension induced by AMPA (35 ± 5 mmHg before pretreatment, 43 ± 6 mmHg after pretreatment). Control injections with D-NAME did not affect resting values or the response to AMPA. The present study shows that stimulation of AMPA receptors in the NTS activates both vasodilatatory and vasoconstrictor mechanisms and that the vasodilatatory mechanism depends on production of nitric oxide in the NTS. Copyright © 2006 the American Physiological Society.
Resumo:
The present study investigated the central role of angiotensin II and nitric oxide on arterial blood pressure (MAP) in rats. Losartan and PD123349 AT 1 and AT 2 (selective no peptides antagonists angiotensin receptors), as well as FK 409 (a nitric oxide donor), N W-nitro-L-arginine methyl ester (L-NAME) a constituve nitric oxide synthase inhibitor endothelial (eNOSI) and 7-nitroindazol (7NI) a specific neuronal nitric oxide synthase inhibitor (nNOSI) were used. Holtzman strain, (Rattus norvergicus) weighting 200-250 g were anesthetized with zoletil 50 mg kg -1 (tiletamine chloridrate 125 mg and zolazepan chloridrate 125 mg) into quadriceps muscle anda stainless steel cannula was stereotaxically implanted into their Lateral Ventricle (LV). Controls were injected with a 0.5 μl volume of 0.15 M NaCl. Angiotensin II injected into LV increased MAP (19±3 vs. control 3±1 mm Hg), which is potentiated by prior injection of L-NAME in the same site 26±2 mm Hg. 7NI injected prior to ANG II into LV also potentiated the pressor effect of ANG II but with a higher intensity than L-NAME 32±3 mm Hg. FK 409 inhibited the pressor effect of ANG II (6±1 mm Hg). Losartan injected into LV before ANG II influences the pressor effect of ANG II (8±1 mm Hg). The PD 123319 decreased the pressor effects of ANG II (16±1 mm Hg). Losartan injected simultaneously with FK 409 blocked the pressor effect of ANG II (3±1 mm Hg). L-NAME produced an increase in the pressor effect of ANG II, may be due to local vasoconstriction and all at once by neuronal NOS inhibition but the main effect is of the 7-NIT an specific nNOS inhibitor. The AT 1 antagonist receptors improve basal nitric oxide (NO) production and release. These data suggest the involvement of constitutive and neuronal NOS in the control of arterial blood pressure induced by ANG II centrally, evolving AT 1 receptor-mediated vasoconstriction and AT 2 receptor-mediated vasodilatation. These results were confirmed by the experiment using FK 409. © 2006 Asian Network for Scientific Information.
Resumo:
Purpose: Bone maintenance after mandibular reconstruction with autogenous iliac crest may be disappointing due to extensive resorption in the long term. The potential of the guided-bone regeneration (GBR) technique to enhance the healing process in segmental defects lacks comprehensive scientific documentation. This study aimed to investigate the influence of polylactide membrane permeability on the fate of iliac bone graft (BG) used to treat mandibular segmental defects. Materials and Methods: Unilateral 10-mm-wide segmental defects were created through the mandibles of 34 mongrel dogs. All defects were mechanically stabilized, and the animals were divided into 6 treatment groups: control, BG alone, microporous membrane (poly L/DL-lactide 80/20%) (Mi); Mi plus BG; microporous laser-perforated (15 cm2 ratio) membrane (Mip), and Mip plus BG. Calcein fluorochrome was injected intravenously at 3 months, and animal euthanasia was carried out at 6 months postoperatively. Results: Histomorphometry showed that BG protected by Mip was consistently related to larger amounts of bone compared with other groups (P ≤ .0001). No difference was found between defects treated with Mip alone and BG alone. Mi alone rendered the least bone area and reduced the amount of grafted bone to control levels. Data from bone labeling indicated that the bone formation process was incipient in the BG group at 3 months postoperatively regardless of whether or not it was covered by membrane. In contrast, GBR with Mip tended to enhance bone formation activity at 3 months. Conclusions: The use of Mip alone could be a useful alternative to BG. The combination of Mip membrane and BG efficiently delivered increased bone amounts in segmental defects compared with other treatment modalities. © 2008 American Association of Oral and Maxillofacial Surgeons.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
With the emergence of new genetic lines due to intense breeding improvement on swine production in recent years, there is the need to adapt more accurately diets for the current sows, which have higher nutritional demands. The use of functional amino acids aimsto optimize the sows production and among these amino acids arginine has excelled. Arginine is involved in several important metabolic pathways, for example, it serves as a substrate forsynthesis of protein, creatine, nitric oxide, polyamines, citrulline, agmatine, ornithine, proline, and glutamate. It also helps to stimulate the secretion of some hormones such as insulin, prolactin, and growth hormone.As arginine plays such important roles, its supplementation has been suggested in lactation feed once it may enhance the development of the mammary gland and milk nutritional profile, thus, providing a better piglet development.Thus, the objective was to evaluate the effect of lactation feed supplementation with L-Arginine on the productive performance of primiparoussows and their respective litter.One hundred forty sows from the same genetic lineage on a commercial farm, located in the city of Oliveira, MG were used in this study, in a completely randomized design with five treatments: control diet without amino acid supplementation and four diets with increasing levels of L-Arginine supplementation (containing 98.5% purity) - 0.5, 1.0, 1.5, and 2.0%. Each treatment hadtwenty-eight swine sows, and the experimental unit was the sowand its litter.It was used ‘on top’ amino acid supplementation.All data was submitted to variance analysis using the SAEG Software: version 9.1 (SAEG, 2005).The data relating to days of lactation were compared by Tukey test (5%). L-Arginine supplementation levels in lactation feed did not influence (P>0.05) average daily feed intake, body condition variables, and blood parameters of the sows (urea, creatinine, and non-esterified fatty acids) as well as it did not affect the dry matter, crude protein, and amino acid profile of milk and the litter performance. There was effect (P<0.05) of days of lactation on the percentage of crude protein and amino acids in milk, which reduced througout the days of lactation. The L-Arginine supplementation on the lactation diet at levels of 0.5, 1.0, 1.5, and 2.0% did not influence the sow and its respective litter performance.
Resumo:
O Óxido Nítrico (NO-) é uma molécula de sinalização celular que regula o desenvolvimento embrionário pré-implantacional. Nós investigamos o papel do NO- no cultivo de embriões bovinos produzidos in vitro, através do uso de N-Nitro-L-Arginina Metil Ester (L-NAME), um inibidor da produção de NO-, e L-arginina (ARG), um precursor de NO-, em diferentes períodos de cultivo (ativação do genoma embrionário e compactação). Foram avaliados seus efeitos sobre as taxas de desenvolvimento, cinética do desenvolvimento, qualidade embrionária, e expressão gênica. Os embriões foram produzidos por maturação e fertilização in vitro de oócitos aspirados de ovários provenientes de abatedouro frigorífico. No experimento 1, as taxas de desenvolvimento foram avaliadas em SOFaa na presença de L-NAME em diferentes períodos: do 1º ao 4º dia de cultivo (LN1-4), do 4º ao 8º (LN4-8) e do 1º ao 8º dia de cultivo (LN1-8). A inibição foi prejudicial a partir do 4º dia de cultivo (grupos LN4-8 e LN1-8), ao reduzir as taxas de eclosão (17,3%±13,44 e 13,7%± 14,51, respectivamente, p<0,05). Entretanto, o efeito mais negativo ocorreu do 1º ao 8º dia (LN1-8) em que a taxa de blastocisto foi significativamente menor comparada ao controle (29,4%±3,72 vs 47,8%±11,34, respectivamente, p<0,05). Por isso no experimento 2, a ARG (1, 10 e 50mM) foi adicionada desde o 1º dia de cultivo. As taxas de blastocisto usando 1 e 10mM de ARG foram similares ao controle (48%±13,03 e 34,2%±3,92 vs 49,4%±4,82, respectivamente, p>0,05), mas 50mM prejudicou a taxa de desenvolvimento embrionário (10,7%±7,24, p<0,001). No experimento 3, ARG a 1mM foi adicionada do 5º ao 8º dia de cultivo. Foram observadas taxas de desenvolvimento similares ao grupo GLN (somente com glutamina). Mas comparada ao controle (sem ambos os aminoácidos), rendeu melhores taxa de eclosão (54,8%±6,9 vs 41,4%±11,47, respectivamente, p<0,05) e qualidade embrionária (84,8%±2,63 vs 52%±8,62, respectivamente, p<0,05), mas não de taxa de blastocisto (49,4%±6,5 vs 49,4%±4,8, respectivamente, p>0,05). Neste período a produção de NO- foi positivamente correlacionada com a taxa de eclosão (R²=96,4%, p<0,001) e a qualidade embrionária (R²=75,5%, p<0,05). Adicionalmente, embriões foram cultivados na presença de L-NAME e ARG simultaneamente (grupo ARG/LN), do 5º ao 8º dia de cultivo, e os transcritos de OCT-4 e INT-t foram quantificados por PCR tempo real. Foi encontrada expressão similar de OCT-4 (p>0,05), mas redução de 1,8x e 1,5x de INT-t em relação aos grupos controles ARG e GLUT (p<0,05), respectivamente. Esses dados fornecem evidências da contribuição do NO-, principalmente no período entre os estágios de mórula e blastocisto, para a melhoria da eclosão e qualidade embrionária. A produção de NO- é requerida para o desenvolvimento pré-implantacional de embriões bovinos produzidos in vitro, e pode ser mediada pela suplementação do meio de cultivo com ARG.
Resumo:
Historicamente conhecida por suas ações sobre o sistema reprodutor, hoje se sabe que a ocitocina (OT) também pode contribuir para a regulação da homeostase cardiovascular e hidroeletrolítica. A OT é produzida nos núcleos supra-óptico e paraventricular do hipotálamo e liberada para o plasma a partir de terminais neurais da pituitária posterior, no entanto, muitos estudos identificaram locais extra-cerebrais de produção OT, incluindo o coração e o endotélio vascular. A ativação de seus receptores em células endoteliais, bem como em sistemas hipotalâmicos/hipofisários e cardíaco, pode resultar na produção de óxido nítrico (NO). O presente trabalho teve como objetivo verificar o papel do NO na regulação da secreção de peptídeo natriurético atrial (ANP) estimulada por OT em cultura primária de cardiomiócitos de embriões de camundongos. Para tal, corações de embriões de camundongos Balb C, com 19 a 21 dias de vida intra-uterina, foram isolados e cultivados para os ensaios com OT e demais substâncias interferentes na síntese de NO e GMPc seu segundo mensageiro. A adição de concentrações crescentes de OT (0.1, 1, 10 e 100 μM) induziu aumento proporcional na secreção de ANP e nitrato para o meio, confirmando a ação estimuladora da OT em cardiomiócitos. O bloqueio da liberação de ANP estimulada por OT (10 μM) foi observada após adição de Ornitina Vasotocina (CVI-OVT) (100 μM), um antagonista específico de OT. Este antagonista inibiu a secreção basal de ANP, quando adicionado individualmente, sugerindo que a OT pode atuar via mecanismo autócrino, tônico estimulatório sobre a secreção de ANP. Amplificação da secreção de ANP estimulada por OT (10 μM) foi observada após sua associação com L-NAME, um inibidor da sintase de óxido nítrico (NOS) (600 μM), e ODQ (100 μM), um inibidor da guanilato ciclase solúvel, sugerindo a ocorrência de feedback negativo nitrérgico na liberação de ANP estimulada por OT no cardiomiócito. Os resultados obtidos mostraram modulação nitrérgica inibidora sobre a secreção de ANP estimulada por OT.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)